Tempus AI (NASDAQ:TEM – Get Free Report) and biote (NASDAQ:BTMD – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Analyst Ratings
This is a summary of current ratings and target prices for Tempus AI and biote, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tempus AI | 1 | 10 | 11 | 0 | 2.45 |
| biote | 1 | 1 | 1 | 1 | 2.50 |
Tempus AI currently has a consensus price target of $79.37, indicating a potential upside of 5.15%. biote has a consensus price target of $2.50, indicating a potential upside of 138.10%. Given biote’s stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than Tempus AI.
Volatility and Risk
Profitability
This table compares Tempus AI and biote’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tempus AI | -12.54% | -47.00% | -9.44% |
| biote | -1.08% | -8.84% | 4.64% |
Earnings and Valuation
This table compares Tempus AI and biote”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tempus AI | $1.51 billion | 9.02 | -$245.03 million | ($1.06) | -71.21 |
| biote | $183.53 million | 0.21 | $27.05 million | ($0.10) | -10.50 |
biote has lower revenue, but higher earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
24.2% of Tempus AI shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 24.3% of Tempus AI shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
biote beats Tempus AI on 10 of the 15 factors compared between the two stocks.
About Tempus AI
Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
